Henry Du
About Henry Du
Henry Du, age 46, serves as Vice President of Finance and Accounting and interim Chief Financial Officer of Alpha Cognition Inc., appointed effective October 21, 2024 . He brings 20+ years of corporate accounting and finance experience in life sciences, including leading Amplify Surgical to consistent positive EBITDA and doubling average daily operating liquidity, and establishing commercial accounting policy for a Japan product launch at HUYABIO International . Mr. Du executed Section 906 certification for ACOG’s FY2024 Form 10-K, affirming fair presentation of financial condition and results of operations . Performance metrics such as TSR, revenue growth, and EBITDA growth tied specifically to his tenure are not disclosed in company filings .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Amplify Surgical | Senior Vice President of Accounting & Administration | Nov 2022–Oct 2024 | Led finance/accounting, HR, payroll, compliance, legal, IR; helped achieve consistent positive EBITDA and profitability; doubled average daily operating liquidity . |
| HUYABIO International | VP Finance & Senior Corporate Controller | Sep 2021–Nov 2022 | Established commercial accounting policy for product launch in Japan . |
| Eledon Pharmaceuticals (formerly Novus Therapeutics) | Leadership roles in finance/accounting | May 2018–Sep 2021 | Corporate finance responsibilities at a publicly traded clinical-stage biopharma . |
| United Auto Credit | Finance leadership | Aug 2017–May 2018 | Corporate finance responsibilities . |
| Avanir Pharmaceuticals | Finance leadership | Mar 2010–Aug 2017 | Corporate finance responsibilities at a specialty pharma company . |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| None disclosed | — | — | Filings do not list external public company directorships or committee roles for Mr. Du . |
Fixed Compensation
| Component | 2025 Terms | Notes |
|---|---|---|
| Base Salary ($) | $275,000 | As per employment agreement; current annual base salary . |
| Target Bonus (%) | 40% of base salary | Eligible yearly bonus set at 40% of base salary . |
| Actual Bonus Paid ($) | Not disclosed | No specific payout disclosed for Mr. Du in FY2024/2025 filings . |
Performance Compensation
| Incentive Type | Metric(s) | Weighting | Target | Actual/Payout | Vesting |
|---|---|---|---|---|---|
| Annual Cash Bonus | Not specified | Not disclosed | 40% of base salary | Not disclosed | N/A . |
| Stock Options | Time-based; no performance metrics | N/A | Initial grant: 32,000 options | Grant disclosed; fair value not disclosed | Vests equally on a quarterly basis over 12 quarters beginning Oct 21, 2024 . |
| Exercise Price (Options) | — | — | — | Weighted average exercise price $10.84 | As disclosed in proxy New Incentive Plan illustration for Mr. Du . |
Equity Ownership & Alignment
| Item | Detail | Date/Status |
|---|---|---|
| Total Beneficial Ownership (voting) | Less than 1% of common shares and total voting stock | As of April 30, 2025 . |
| Direct/Common Shares Owned | Not separately disclosed | Beneficial ownership table does not specify direct common shares for Mr. Du; see options breakdown below . |
| Vested Options | 5,334 | As disclosed; excludes unvested . |
| Unvested Options | 26,666 | As disclosed . |
| Vesting Schedule | 32,000 options vest equally quarterly across 12 quarters starting Oct 21, 2024 | Employment agreement terms . |
| Shares Pledged | None disclosed | No pledging disclosure for Mr. Du; Company hedging/monetization transactions prohibited under share trading policy . |
| Hedging | Prohibited (prepaid forwards, swaps, collars, exchange funds) | Policy applies to directors and officers . |
| Clawback Policy | Mandatory recovery of erroneously awarded incentive-based compensation for current/former executive officers upon accounting restatement; effective Nov 12, 2024 | Complies with SEC Rule 10D-1 and Nasdaq Listing Rule 5608 . |
| Ownership Guidelines | Not disclosed | No executive stock ownership guideline disclosures identified in filings . |
Employment Terms
| Term | Detail |
|---|---|
| Role | Vice President of Finance and Accounting and interim Chief Financial Officer . |
| Start Date | October 21, 2024 . |
| Contract Term/At-Will | Not disclosed in filings for Mr. Du . |
| Severance | Not disclosed for Mr. Du; severance terms are disclosed for other executives (CEO, COO) but not for Mr. Du . |
| Change-of-Control | Not disclosed for Mr. Du; CoC terms disclosed for other executives (CEO, COO) but not for Mr. Du . |
| Options Grant | 32,000 options under the 2023 Stock Option Plan, vesting quarterly over 12 quarters from Oct 21, 2024 . |
| Bonus Eligibility | Eligible for 40% of base salary annual bonus . |
| 10b5-1 Plan | Not disclosed . |
| Late Filings | One late Form 3 (no transactions) noted for Mr. Du in FY2024 Section 16(a) reporting . |
Investment Implications
- Retention and alignment: Compensation is equity-heavy with a multi-year, time-based vesting schedule that incentivizes continuity through 2027; clawback and hedging prohibitions strengthen shareholder alignment and reduce misalignment risk .
- Ownership and selling pressure: Reported beneficial ownership is <1%; vested options are modest (5,334) relative to unvested (26,666), suggesting limited near-term selling pressure absent additional grants; absence of pledging disclosure reduces collateral-related risk .
- Governance and reporting: A late Form 3 is a minor procedural flag; however, Mr. Du signed Section 906 certification for the FY2024 10-K, underscoring accountability for financial reporting amid commercialization scaling .
- Execution context: Company risk factors emphasize reliance on successful commercialization of ZUNVEYL and potential need for additional capital; CFO role is central to managing liquidity, access, and controls in this environment, heightening the importance of retention and performance-linked oversight .
Notes:
- All figures and terms are sourced from ACOG’s 2025 DEF 14A and FY2024 10-K. Option exercise price and counts for Mr. Du reflect the DEF 14A disclosures, including vesting terms and weighted average exercise price .